Table 3.
HR (95% CI) of MACCEs according to FIB5-CRP group in the three models
| Groups | Events, n (%) | Model 1 | Model 2 | Model 3 | |||
|---|---|---|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | ||
| high FIB-5 and low CRP | 97 (8.4) | Ref. | Ref. | Ref. | |||
| low FIB-5 and low CRP | 106 (9.2) | 1.21 (0.91–1.60) | 0.183 | 1.13 (0.85–1.50) | 0.412 | 1.12 (0.84–1.49) | 0.438 |
| high FIB-5 and high CRP | 125 (10.8) | 1.68 (1.28–2.19) | < 0.001 | 1.40 (1.06–1.83) | 0.017 | 1.39 (1.06–1.83) | 0.017 |
| low FIB-5 and high CRP | 160 (13.9) | 2.04 (1.58–2.65) | < 0.001 | 1.67 (1.28–2.18) | < 0.001 | 1.66 (1.27–2.17) | < 0.001 |
HR hazard ratio; CI confidence intervals; FIB-5 fibrosis-5; CRP C-reactive protein;
Model 1: adjusted for age, gender, SBP, DBP, heart rate, and BMI.
Model 2: adjusted for Model 1 + BNP, hematocrit, UA, WBC, Creatinine, Sodium, Potassium, LDL-C, LAD, and LVEF.
Model 3: adjusted for Model 2 + history of hypertension, valvular heart disease, atrial fibrillation, and use of aldosterone antagonist, Beta-Blockers, diuretics, statins, digoxin, ACEI/ARB/ARNI, and SGLT2i